Probody therapeutics- antibodies that are masked in circulation and cleaved in the tumor to exert a tumor-killing effect locally & selectly

[Scout4answers]

I am posting this not as a stock recommendation but as a question, does anyone know about this technology ? A potentially useful immuno therapy ?

June 23, 2022 | 16:02 ET~

CytomX Therapeutics

CTMX-NSDQ Rating

Outperform

Price: Jun-22

$1.80 Target $9.00

Initiating at OP: We Are 'Pro Bodies' on Near-Term

Risk Reward

Bottom Line:

We are initiating coverage of CytomX Therapeutics (CTMX-NSDQ) with an Outperform

rating and a $9 target price. CTMX is developing Probody therapeutics — antibodies that

are masked in circulation and cleaved in the tumor to exert a tumor-killing effect locally

and selectively. CTMX currently trades with a negative EV and we believe upcoming

CX-2009 Phase 2 readout with in 2H represents a significant near-term opportunity for

the stock. We are positive on the story given the company’s first-in-category Probody

pipeline and see a positive risk/reward heading into CX-2009's data update.

Key Points

The Probody platform is a differentiated approach to targeted immune oncology.

While traditional antibody-based therapies have proven effective in the treatments

of almost every type of cancer, their propensity to kill healthy cells in addition to

tumor cells can lead to serious side effects and a decrease in tolerability. CTMX’s

Probody technology aims to avoid this by administering a non-active form of the drug

that is activated once cleaved by proteases that are highly expressed in the tumor

environment. Antibodies that are preferentially active in the tumor should spare more

healthy cells and increase drug tolerability and therefore duration of treatment and

overall efficacy. CTMX is advancing multiple programs internally and in combination

with partners including ABBV, BMY, AMGN, and TAK.

Our CX-2009's numbers are modest but the risk-reward for CTMX appears

skewed to the upside. CTMX is trading at a negative EV despite several first-in-class

opportunities in its pipeline, including CX-2009, a CD166 antibody being pursued in non-

HER2 amplified breast cancer. While the investor community view the data generated

by CX-2009 as modest, the drug appears active to us in late-line ER+/HER2- patients

where there are few options for patients and activity seems to be correlated with high

CD166 expression which gives us confidence in the mechanistic rationale for the asset.

On positive 2H data, CX-2009 alone could be worth $6-8 per share.

Collaborative agreements can provide additional revenue as clinical trials

continue. CTMX has partnership and collaboration agreements with AbbVie, Amgen,

Takeda, and Bristol Myers Squibb, including mid-stage programs partnered with

ABBV and BMY. Management expects to provide an update from the Phase 2 study of

CX-2029 (ABBV) in squamous cell non-small cell lung cancer in 2H, a high unmet need

indication for which the Street has low expectations.

[Jac_J]

Price: Jun-22

$1.80 Target $9.00

Ok . Im in.

[cesces in reply to Jac_J]

Many a slip twixt the cup and the lip.

[Scout4answers in reply to Jac_J]

Keep in mind that this is merely the opinion of a 30 year old whose job is, to promote the buying of this stock. I believe that there is more accumulated knowledge on this board about the potential for immuno therapies then that particular stock analyst possesses.

[j-o-h-n in reply to Jac_J]

I'll wait till it get in it on Ebay $18.00.... (original box and free shipping)...

Good Luck, Good Health and Good Humor.

j-o-h-n Wednesday 06/29/2022 6:38 PM DST

[allie2020]

Very interesting, thanks for posting. The chart sure goes from the upper left to the lower right over the past five years. I'm unqualified to even hazard a guess as to its possible effectiveness as a treatment. Certainly lots of promising things happening these days in the treatment of PCa.

finance.yahoo.com/quote/CTM...

[NickJoy]

Thanks for posting this. I hope it proves to be effective. It is interesting to read the analysis from an investors point of view. I have watched new developments posted here and often wondered if I should invest in some of the 'likely' candidates in order to fund future treatments for my husband. It seems to me that investing in radioisotopes would be a good idea but I don't really know anything about the market. Given that many of us keep a close eye on pharmaceutical developments for PCA, investment utilising this knowledge may be a road to some degree of freedom from the financial restrictions imposed on us by the powers that be for our medical needs. Where to start? That is the tricky bit......

[Scout4answers in reply to NickJoy]

CT of Stage 1 and 2 drug stocks are a notoriously risky bets, watching this board will tell you how many times promising drugs fail. Investing in their potential partners or a pharmaceutical ETF would be a safer place to put your money, you may loose some money but not likely to loose all of it.

[NickJoy in reply to Scout4answers]

Thank you that is very helpful.

[Rolphs]

I hope we keep getting companies to risk there capital to find new PCa drugs. The odds are daunting: “Only 5 in 5,000 drugs that enter preclinical testing progress to human testing. One of these 5 drugs that are tested in people is approved. The chance for a new drug to actually make it to market is thus only 1 in 5,000.” Not very good odds for a huge amount of money. IMO it’s the most likely a cure or at least something that stops MPCa progression will only come from a company like this. For that reason I do invest in some of these speculative firms. Thanks for sharing.

[IRussellCoop]

Bad day at the office...Unless one was swimming in put options... CytomX Therapeutics (CTMX) plunged 32% following the release of clinical trial results.